Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (93)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Skarlos, D. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skarlos, D. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:601-607, 1994
© 1994 European Society for Medical Oncology

research-article

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer

A Hellenic Co-operative Oncology Group study

D. V. Skarlos, E. Samantas, P. Kosmidis, G. Fountzilas, M. Angelidou, Ph. Palamidas, N. Mylonakis, A. Provata, E. Papadakis, G. Klouvas, D. Theocharis, E. Panousaki, E. Boleti, G. Sphakianoudis, N. Pavlidis and For the Lung Cancer Study group*

Correspondence to: Dr. D. V. Skarlos, Hellenic Co-operative Oncology Group, Mesogeion 82, 115 27 Athens/Ambelokipi, Greece

PURPOSE:: To compare the efficacy and toxicity of etoposide and cisplatin (EP) with etoposide and carboplatin (EC) in combination with irradiation in small-cell lung cancer (SCLC).

METHODS:: Previously untreated patients (pts) with SCLC and measurable or evaluable disease were randomized to receive either cisplatin 50 mg/m2 on days 1–2 or carboplatin 300 mg/m2 on day 1, both combined with etoposide 300 mg/m2 on days 1–3 every 21 days for 6 treatment cycles. The vast majority of responding limited disease (LD) pts and complete responders (CR) with extensive disease (ED), also received thoracic irradiation (TI) and prophylactic cranial irradiation (PCI) concurrently with the third cycle.

RESULTS:: Of the 147 patients registered, 143 were eligible; median performance status (PS, WHO) was 1, and tumour stage was LD in 41 pts of each treatment group. The mean delay between cycles was 8 days in the EP group and 9 in the EC group increasing in both arms with the number of treatment courses. The drug dose administered per unit time as a proportion of the protocol dose was 74% and 80% for the two groups respectively. Leukopenia, neutropenic infections, nausea, vomiting, neurotoxicity and hyperergic reactions were more frequent and/or severe in the EP group. The CR rates were 57% and 58% for EP and EC respectively. Median survival for all pts was 12.5 and 11.8 months, respectively.

CONCLUSION:: Both treatments proved to be effective, with no differences in response and survival between the two treatment arms. The EC regimen was associated with significantly less toxicity.

small-cell lung cancer (SCLC), cisplatin, etoposide, carboplatin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
G. Chen, M. Huynh, L. Fehrenbacher, H. West, P. N. Lara Jr, L. L. Yavorkovsky, M. Russin, D. Goldstein, D. Gandara, and D. Lau
Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer
J. Clin. Oncol., March 20, 2009; 27(9): 1401 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S M Lee, L E James, W Qian, S Spiro, T Eisen, N H Gower, D R Ferry, D Gilligan, P G Harper, J Prendiville, et al.
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer
Thorax, January 1, 2009; 64(1): 75 - 80.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Hermes, B. Bergman, R. Bremnes, L. Ek, S. Fluge, C. Sederholm, S. Sundstrom, L. Thaning, J. Vilsvik, U. Aasebo, et al.
Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial
J. Clin. Oncol., September 10, 2008; 26(26): 4261 - 4267.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Yu, X. Zhang, J. Liu, P. Yuan, W. Tan, Y. Guo, T. Sun, D. Zhao, M. Yang, J. Liu, et al.
Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
Clin. Cancer Res., May 1, 2008; 14(9): 2878 - 2886.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
T. Sher, G. K. Dy, and A. A. Adjei
Small Cell Lung Cancer
Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Rudin, R. Salgia, X. Wang, L. D. Hodgson, G. A. Masters, M. Green, and E. E. Vokes
Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103
J. Clin. Oncol., February 20, 2008; 26(6): 870 - 876.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al.
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Schmittel, L. F. von Weikersthal, M. Sebastian, P. Martus, K. Schulze, P. Hortig, M. Reeb, E. Thiel, and U. Keilholz
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer
Ann. Onc., April 1, 2006; 17(4): 663 - 667.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Thatcher, W. Qian, P. I. Clark, P. Hopwood, R. J. Sambrook, R. Owens, R. J. Stephens, and D. J. Girling
Ifosfamide, Carboplatin, and Etoposide With Midcycle Vincristine Versus Standard Chemotherapy in Patients With Small-Cell Lung Cancer and Good Performance Status: Clinical and Quality-of-Life Results of the British Medical Research Council Multicenter Randomized LU21 Trial
J. Clin. Oncol., November 20, 2005; 23(33): 8371 - 8379.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand
Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost
Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30.
[Abstract] [PDF]

Home page
 JCOHome page
M. Neubauer, J. Schwartz, J. Caracandas, P. Conkling, D. Ilegbodu, T. Tuttle, and L. Asmar
Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Patients With Extensive Small-Cell Lung Cancer With Eastern Cooperative Oncology Group Performance Status of 2, or Age >= 70 Years
J. Clin. Oncol., May 15, 2004; 22(10): 1872 - 1877.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Rudin, M. Kozloff, P. C. Hoffman, M. J. Edelman, R. Karnauskas, R. Tomek, L. Szeto, and E. E. Vokes
Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer
J. Clin. Oncol., March 15, 2004; 22(6): 1110 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Laskin, A. Sandler, and D. H. Johnson
An Advance in Small-Cell Lung Cancer Treatment--More or Less
J Natl Cancer Inst, August 6, 2003; 95(15): 1099 - 1101.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Reck, J. von Pawel, H.-N. Macha, E. Kaukel, K.-M. Deppermann, R. Bonnet, K. Ulm, S. Hessler, and U. Gatzemeier
Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer
J Natl Cancer Inst, August 6, 2003; 95(15): 1118 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. P. Sculier, J. J. Lafitte, J. Lecomte, T. Berghmans, J. Thiriaux, O. Van Cutsem, A. Efremidis, V. Ninane, M. Paesmans, P. Mommen, et al.
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer
Ann. Onc., September 1, 2002; 13(9): 1454 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. G. De Soyza, J. H. Dark, D. V. Parums, A. Curtis, and P. A. Corris
Donor-Acquired Small Cell Lung Cancer Following Pulmonary Transplantation
Chest, September 1, 2001; 120(3): 1030 - 1031.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. Kelly
New Chemotherapy Agents for Small Cell Lung Cancer
Chest, April 1, 2000; 117 (2009): 156S - 162S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. H. Johnson
Management of Small Cell Lung Cancer* : Current State of the Art
Chest, December 1, 1999; 116 (2009): 525S - 530S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Okamoto, K. Watanabe, Y. Nishiwaki, K. Mori, Y. Kurita, I. Hayashi, M. Masutani, K. Nakata, S. Tsuchiya, H. Isobe, et al.
Phase II Study of Area Under the Plasma-Concentration-Versus-Time Curve-Based Carboplatin Plus Standard-Dose Intravenous Etoposide in Elderly Patients With Small-Cell Lung Cancer
J. Clin. Oncol., November 1, 1999; 17(11): 3540 - 3545.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. E. Groopman and L. M. Itri
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Go and A. A. Adjei
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
J. Clin. Oncol., January 1, 1999; 17(1): 409 - 409.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Alberts and R. T. Dorr
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
Oncologist, February 1, 1998; 3(1): 15 - 34.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.